Stock GKOS GLAUKOS CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Glaukos Corporation

Equities

GKOS

US3773221029

Market Closed - Nyse
Other stock markets
 16:00:02 2024-04-26 EDT 		5-day change 1st Jan Change
99.48 USD -0.63% Intraday chart for Glaukos Corporation +3.09% +25.15%
04-11 Mizuho Securities Adjusts Price Target on Glaukos to $100 From $85, Maintains Neutral Rating MT
04-11 Glaukos Insider Sold Shares Worth $6,008,359, According to a Recent SEC Filing MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Glaukos Insider Sold Shares Worth $6,008,359, According to a Recent SEC Filing
Sector Update: Health Care Stocks Rise Wednesday Afternoon
Glaukos Says iDose TR Assigned Permanent J-Code From US Centers for Medicare and Medicaid Services
Glaukos Corporation Receives Permanent J-Code for iDose TR (travoprost intracameral implant)
Glaukos Insider Sold Shares Worth $1,153,557, According to a Recent SEC Filing
Glaukos Insider Sold Shares Worth $736,000, According to a Recent SEC Filing
Glaukos Insider Sold Shares Worth $423,487, According to a Recent SEC Filing
Glaukos Q4 Non-GAAP Loss Widens, Sales Increase
Glaukos Corporation Reaffirms Financial Guidance for 2024
Glaukos Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
Glaukos Insider Sold Shares Worth $436,041, According to a Recent SEC Filing
Glaukos Preliminary Q4 Net Sales Top Estimates; 2024 Revenue Outlook Reaffirmed; Shares Rise
Glaukos Corporation Announces Preliminary and Unaudited Net Sales for the Fourth Quarter and Full Year of 2023; Reaffirms Net Sales Guidance for the Year 2024
Glaukos Insider Sold Shares Worth $7,334,253, According to a Recent SEC Filing
Sector Update: Health Care Stocks Slipping Late Afternoon
Sector Update: Health Care
Glaukos Shares Jump After US FDA Approves New Drug Application for iDose TR
Sector Update: Health Care Stocks Rise Pre-Bell Thursday
Glaukos Says FDA Approves New Drug Application for iDose TR
Glaukos Corporation Re-Affirms Revenue Guidance for the Year 2023 and 2024
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GKOS Stock
  4. News Glaukos Corporation
  5. Other languages